ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $15,225 | -75.0% | 142 | -71.5% | 0.00% | -100.0% |
| Q4 2022 | $60,821 | +452.9% | 498 | +507.3% | 0.00% | – |
| Q2 2021 | $11,000 | -91.1% | 82 | -88.9% | 0.00% | -100.0% |
| Q4 2020 | $123,000 | +2.5% | 737 | -4.9% | 0.01% | -16.7% |
| Q3 2020 | $120,000 | – | 775 | +19275.0% | 0.01% | – |
| Q1 2020 | $0 | -100.0% | 4 | -94.9% | 0.00% | -100.0% |
| Q3 2019 | $9,000 | 0.0% | 78 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $9,000 | +800.0% | 78 | +766.7% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 9 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | – | 9 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |